Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Master Transcription Regulators02:23

Master Transcription Regulators

Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
Epigenetic Regulation01:46

Epigenetic Regulation

Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
Epigenetic Regulation01:37

Epigenetic Regulation

Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Somatic to iPS Cell Reprogramming01:29

Somatic to iPS Cell Reprogramming

Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012 for this...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: GLYATL1 is associated with metabolic and epigenetic changes and with endocrine resistance in luminal breast cancer.

Clinical epigenetics·2026
Same author

Integrated multi-omic profiling reveals two distinct splenic marginal zone lymphoma subgroups with prognostic relevance.

Blood advances·2026
Same author

Mutant IDH1 blocks neutropoiesis by repressing myeloid progenitor programs.

Blood·2026
Same author

Cost Drivers of Workers' Compensation Low Back Injury Claims in an Academic Health System, 2015-2024.

Journal of occupational and environmental medicine·2026
Same author

GLYATL1 is associated with metabolic and epigenetic changes and with endocrine resistance in luminal breast cancer.

Clinical epigenetics·2026
Same author

Integrating Meaning, Purpose, and Spirituality (MPS) Within Lifestyle Medicine Education and Training: Core Competencies to Support Whole-Person Care.

American journal of lifestyle medicine·2026

Related Experiment Video

Updated: May 16, 2026

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

CDX2-driven leukemogenesis involves KLF4 repression and deregulated PPARγ signaling.

Katrin Faber1, Lars Bullinger, Christine Ragu

  • 1Department of Internal Medicine III, Ulm University, Ulm, Germany.

The Journal of Clinical Investigation
|December 4, 2012
PubMed
Summary

CDX2 promotes acute myeloid leukemia (AML) by repressing KLF4. Targeting the PPARγ pathway can restore KLF4, offering a new therapeutic strategy for AML patients with CDX2 expression.

More Related Videos

Study of Dendritic Cell Development by Short Hairpin RNA-Mediated Gene Knockdown in a Hematopoietic Stem and Progenitor Cell Line In vitro
06:12

Study of Dendritic Cell Development by Short Hairpin RNA-Mediated Gene Knockdown in a Hematopoietic Stem and Progenitor Cell Line In vitro

Published on: March 7, 2022

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists
10:51

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists

Published on: November 15, 2013

Related Experiment Videos

Last Updated: May 16, 2026

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

Study of Dendritic Cell Development by Short Hairpin RNA-Mediated Gene Knockdown in a Hematopoietic Stem and Progenitor Cell Line In vitro
06:12

Study of Dendritic Cell Development by Short Hairpin RNA-Mediated Gene Knockdown in a Hematopoietic Stem and Progenitor Cell Line In vitro

Published on: March 7, 2022

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists
10:51

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists

Published on: November 15, 2013

Area of Science:

  • Hematology
  • Molecular Biology
  • Cancer Research

Background:

  • Aberrant CDX2 expression drives acute myeloid leukemia (AML) leukemogenesis, presenting it as a potential therapeutic target.
  • CDX2 exhibits context-dependent functions, acting as a tumor suppressor in colon cancer but oncogenic in AML.
  • The mechanisms behind CDX2's dual role and its leukemogenic effectors remain poorly understood.

Purpose of the Study:

  • To elucidate the effectors of CDX2's leukemogenic activity in AML.
  • To investigate the context-dependent regulation of CDX2 in AML versus colon cancer.
  • To identify novel therapeutic strategies targeting CDX2 function in AML.

Main Methods:

  • Investigated the role of transcription factor KLF4 in CDX2-mediated leukemogenesis.
  • Analyzed tissue-specific promoter binding and epigenetic modifications affecting KLF4 regulation by CDX2.
  • Examined the PPARγ signaling pathway in CDX2-associated AML and tested PPARγ agonists.

Main Results:

  • Repression of KLF4 is crucial for CDX2's oncogenic activity in AML.
  • CDX2 differentially regulates KLF4 in AML and colon cancer via distinct promoter binding and epigenetic mechanisms.
  • Deregulation of PPARγ signaling is a hallmark of CDX2+ AML; PPARγ agonists reactivate KLF4 and selectively kill leukemic cells.

Conclusions:

  • CDX2's leukemogenic function in AML involves KLF4 repression through tissue-specific mechanisms.
  • PPARγ pathway modulation offers a promising therapeutic approach to restore KLF4 and treat CDX2+ AML.
  • Understanding CDX2's dual role provides insights into context-dependent transcription factor activity and cancer therapy.